TCT 2025 Top Trials

12 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Missed TCT 2025? Get the practice-changing highlights right here. This is your express summary of the TOP late-breaking clinical trials from San Francisco, packed into one video.

We cover the groundbreaking new data on:
✅ PCI vs. CABG (FAME 3 & NOBLE 10-Year)
✅ TAVR vs. SAVR (PARTNER 3 7-Year)
✅ Shockwave (IVL) vs. Cutting Balloon (SHORTCUT)
✅ Drug-Coated Balloons (SOLUTION De Novo)
✅ And much more...

From the 10-year NOBLE trial results for left main disease to the surprising findings of the PROCTOR trial for saphenous vein grafts, TCT 2025 delivered major updates. In this episode of Cardio Buzz, we sift through the data to give you the key takeaways on mechanical thrombectomy for PE (STORM-PE), new strategies for STEMI (I-MODERN), and the head-to-head battles of IVL vs. cutting balloons (SHORTCUT & VICTORY). We also analyze the new era of drug-coated balloons, comparing the SOLUTION sirolimus-eluting balloon to DES and other platforms.

What is the one finding from TCT 2025 that will change YOUR practice first? Share your biggest takeaway in the comments below!

???? Subscribe to Cardio Buzz for weekly cardiology updates, deep dives, and trial summaries:


00:00 Welcome to Cardio Buzz: TCT 2025 Highlights
00:57 The Power of Music in the Cath Lab
02:03 PCI vs. Coronary Artery Bypass Graft
04:04 Advancements in TAVR and SAVR
05:11 Left Atrial Appendage Occlusion Insights
06:12 Mechanical Thrombectomy for Pulmonary Embolism
07:43 Treating Saphenous Vein Grafts vs. Native Vessels
09:50 ST Elevation MI: New Trials and Findings
12:22 Shockwave Technology and Alternatives
14:07 Drug-Coated Balloons: The Latest Research
17:28 Conclusion: Key Takeaways from TCT 2025

#TCT #cardiology #interventionalcardiology
#latebreakingnews #trials #pci #tavr #StructuralHeart #DrugCoatedBalloon #shockwave #ivl #pulmonaryembolism
Categoria
Cardiology
Commenta per primo questo video.

Prossimo